Piramal Pharma plunges 48% since listing on selling pressure

Piramal Pharma is currently trading at valuations of 31.4 times FY23 estimated earnings and 17 times FY23 estimated EV/EBITDA.

from Stocks-Markets-Economic Times
Read The Rest:economictimes...